Aptose Biosciences Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aptose Biosciences Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($25.43M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | ($11.96M) | Mar 26, 2024 |
| FY2023 | Sep 30, 2023 | ($11.45M) | Mar 26, 2024 |
| FY2023 | Jun 30, 2023 | ($14.13M) | Mar 26, 2024 |
| FY2023 | Mar 31, 2023 | ($13.68M) | Mar 26, 2024 |
| FY2023 | Dec 31, 2022 | ($10.00M) | Mar 26, 2024 |
| FY2023 | Sep 30, 2022 | ($9.78M) | Mar 26, 2024 |
| FY2023 | Jun 30, 2022 | ($10.57M) | Mar 26, 2024 |
| FY2023 | Mar 31, 2022 | ($11.48M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($24.32M) | Mar 24, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.13M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $12.99M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $51.03M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $82.53M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $126.26M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $100.48M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $16.87M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $11.97M | Mar 12, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.67M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $15.89M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $13.29M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $8.29M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $7.35M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $6.55M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.79M | Mar 10, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.54M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($2.90M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2022 | $37.74M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $74.24M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $118.92M | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | $93.93M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $14.08M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $10.20M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $7.33M | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (36) | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | (1) | Mar 26, 2024 |
| FY2023 | Sep 30, 2023 | (1) | Mar 26, 2024 |
| FY2023 | Jun 30, 2023 | (2) | Mar 26, 2024 |
| FY2023 | Mar 31, 2023 | (2) | Mar 26, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 26, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Mar 26, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Mar 26, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 24, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (36) | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | (1) | Mar 26, 2024 |
| FY2023 | Sep 30, 2023 | (1) | Mar 26, 2024 |
| FY2023 | Jun 30, 2023 | (2) | Mar 26, 2024 |
| FY2023 | Mar 31, 2023 | (2) | Mar 26, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 26, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Mar 26, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Mar 26, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 24, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.15M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $9.25M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $36.97M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $39.11M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $117.39M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $79.84M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $15.30M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $10.63M | Mar 12, 2019 |